Interestingly, ruxolitinib has previously been shown to elevate glucose levels in myeloproliferative neoplasms, which are clonal disorders of hematopoietic stem cells driven by gain-of-function mutations in e.g., JAK2 (Nageswara Rao et al, 2019). Here, JAK2 is linked to myeloproliferative neoplasm.